Molecular Partners AG ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $5.5M0.0% YoYTTM through 30 Jun 2025
Net Income -$77.7MTTM through 31 Dec 2025
Free Cash Flow -$65.6MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
| Operating Margin | -1,336.3% |
| Net Margin | -1,417.4% |
Returns
-76.7%ROE
-60.4%ROA
Balance Sheet Health
Debt / Equity0.05x
Current Ratio4.44x
Net Debt-$89.3Mnet cash position
Cash & Equivalents$82.7M
Quality Metrics
Piotroski F-Score1 / 9
FCF Margin-1,197.7%
Rule of 40-1,169.1
Earnings-Beat Rate33.3%
Multi-Year Trend
RevenueFY2024: $5M
Diluted EPSFY2025: $-1.65
Dividend
No dividend
Capital Allocation
Capex Intensity13.0%
Segment Performance
No segment data available.
Financials converted at 0.7917 from CHF.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.